Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects

Movement Disorders

Volumn 25, Issue 12, 2010, Pages 1924-1928

  Hyson, H Christopher ^a   Kieburtz, Karl ^b   Shoulson, Ira ^b   McDermott, Michael ^b   Ravina, Bernard ^b   De Blieck, Elisabeth A ^b   Cudkowicz, Merit E ^c   Ferrante, Robert J ^d,e  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b UNIVERSITY OF ROCHESTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Coenzyme Q10; Huntington's disease; Safety; Tolerability

Indexed keywords

ALPHA TOCOPHEROL; GELATIN; UBIDECARENONE;

ADULT; ANXIETY DISORDER; ARTICLE; CAPSULE ENDOSCOPE; CHEWABLE TABLET; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FALLING; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUNTINGTON CHOREA; MALE; MUSCLE CRAMP; NAIL GROWTH; OPEN STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PURPURA; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINUSITIS; TISSUE GROWTH; VOMITING;

ANALYSIS OF VARIANCE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; HUNTINGTON DISEASE; MALE; TREATMENT OUTCOME; UBIQUINONE;

EID: 77956802394     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22408     Document Type: Article

References (10)

1. The Huntington's disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2. Browne SE, Bowling AC, MacGarvey U, et al. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 1997;41:646-653. (Pubitemid 27212659)
3. Koroshetz WJ, Jenkins BG, Rosen BR, Beal MF. Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann Neurol 1997;41:160-165.
4. Lodi R, Schapira AH, Manners D, et al. Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000;48:72-76. (Pubitemid 30432433)
5. Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001;57:397-404.
6. Musumeci O, Naini A, Slonim AE, et al. Familial cerebellar ataxia with muscle coenzyme Q10 deficiency. Neurology 2001;56:849-855.
7. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
8. Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3. (Pubitemid 9051179)
9. Huntington Study Group. Unified Huntington's disease Rating Scale: reliability and consistency. Mov Disord 1996;11:136-142.
10. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004;188:491-494.